UPDATE: Credit Suisse Reiterates Outperform Rating, Raises PT on Esperion Therapeutics on Multiple Positive Factors

In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on Esperion Therapeutics ESPR, and raised the price target from $26.00 to $38.00. In the report, Credit Suisse noted, “Study 008 clearly demonstrated the superior efficacy of ETC-1002 over Zetia and surprisingly strong data for the all oral combination ETC-1002 / Zetia. The safety profile was consistent with prior trials and more convincing with larger patient numbers, but long-term safety remains an open question. We are increasing our target to $38 from $26 with an increase to our probability of success to 60% from 55% in statin intolerant patients and to 45% from 33% in residual risk patients. Estimates increase on probability of success and forecast partnership.” Esperion Therapeutics closed on Wednesday at $24.42.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsCredit SuisseJason Kantor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!